Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Irwin

Interventional Pain Medicine Bethesda, MD Doctor of Osteopathy

NPI 1093007643 CMS profile 1384182

6410 Rockledge Dr Ste 421, Bethesda, MD 20817

Open in the dashboard

General payments

$29,866

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Irwin of Bethesda, MD is reported in the CMS Open Payments database as having received $29,866 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,436 45
2024 General $21,569 92
2023 General $4,345 106
2022 General $1,851 30
2021 General $493 9
2019 General $172 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Irwin
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Anna Irwin were reported at $1,436. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Anna Irwin Interventional Pain Medicine median Middle half National median
2019 $172 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $493 $552 $167–$1,554 $132
2022 $1,851 $605 $187–$1,924 $149
2023 $4,345 $671 $195–$1,915 $160
2024 $21,569 $684 $206–$1,837 $164
2025 $1,436 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertos Medical, Inc. $18,522 29 payments
  2. Medtronic, Inc. $3,516 78 payments
  3. Boston Scientific Corporation $2,031 53 payments
  4. Abbott Laboratories $1,413 34 payments
  5. Stryker Corporation $1,092 3 payments
  6. MML US, Inc. $741 8 payments
  7. NuVasive, Inc. $528 5 payments
  8. Nevro Corp. $379 7 payments
  9. AbbVie, Inc. $235 10 payments
  10. Relievant Medsystems, Inc. $147 6 payments
  11. Other $1,262 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,076 268 payments
  2. Consulting Fee $10,250 7 payments
  3. Travel and Lodging $8,540 11 payments
Products named General payments · program years 2019–2025
  1. mild Device Kit Orthopedic $18,522 29 payments
  2. INTELLIS ADAPTIVESTIM $2,939 64 payments
  3. WaveWriter Alpha Prime 16 $1,271 37 payments
  4. MILD DEVICE KIT Instruments $1,017 2 payments
  5. ReActiv8 $741 8 payments
  6. Intracept $533 15 payments
  7. PROCLAIM $445 7 payments
  8. INCEPTIV $409 7 payments
  9. AttraX $308 3 payments
  10. ETERNA $282 7 payments
  11. Other $4,259 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,611

Median for Interventional Pain Management: 1,220

Drug cost

$24,721

Median for Interventional Pain Management: $39,344

Branded share of claims

9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 501 $8,885
Lidocaine Generic 57 $3,821
Baclofen Generic 211 $2,875
Celecoxib Generic 58 $2,032
Gabapentin Generic 119 $1,385
Diclofenac Sodium Generic 110 $1,217
Tramadol Hcl Generic 148 $1,005
Acetaminophen-Codeine Acetaminophen With Codeine Brand 64 $498
Tizanidine Hcl Generic 29 $479
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 49 $441

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$538,217

Of which drugs: $15,059

Medicare patients

945

Average age 77

Services billed

11,421

597 women, 348 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 28%
Diabetes 25%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 80 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $44
$44 — —
Qutenza
  • Averitas Pharma Inc. $37
$37 — —
BOTOX
  • AbbVie, Inc. $31
$31 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $22
$22 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record